Association between B-group vitamins and venous thrombosis: systematic review and meta-analysis of epidemiological studies

Zhou, Kuangguo; Zhao, Ruizhi; Geng, Zhe; Jiang, Lijun; Cao, Yang; Xu, Danmei; Yin, Liuguo; Huang, Liang; Zhou, Jianfeng

doi:10.1007/s11239-012-0759-x

Cited by 15 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rivaroxaban inhibits both free and clot-bound factor Xa, as well as prothrombinase activity. 45 High homocysteine and B vitamin deficiency in the presence of MTHFR C677T homozygosity or compound C677T-A1298C heterozygosity are prothrombotic, 46 and high homocysteine can be normalized by L-methylfolate-vitamin B6-vitamin B12 therapy with reduction of thrombotic potential. 47,48 The authors have studied 300 patients with idiopathic hip ON 9,49-52 but have en-countered only 15 with idiopathic ON limited solely to the knees, demonstrating its rarity, the need for investigation of its etiology, and the need for development of improved treatment regimens.…”

Section: Discussionmentioning

confidence: 99%

Medical Treatment of Osteonecrosis of the Knee Associated With Thrombophilia-Hypofibrinolysis

Glueck¹,

Freiberg²,

Wang³

2014

Orthopedics

View full text Add to dashboard Cite

In 6 patients with stage II knee osteonecrosis, all 6 with thrombophilia and 4 with concurrent hypofibrinolysis, the authors prospectively determined whether anticoagulation with enoxaparin could prevent collapse and progression to osteoarthritis, ameliorate pain, and restore function. The 6 patients were treated with enoxaparin (40 to 60 mg/d for 3 or more months) as mandated by a US Food and Drug Administration-approved protocol. In post-enoxaparin prospective follow-up, patients were reassessed clinically every 4 to 6 months, and radiographs were obtained every year. The 6 patients followed up at 15.1, 7.5, 3.9, 2.25, 2, and 1 year, respectively. None progressed to joint collapse or severe osteoarthritis. Four became and remained asymptomatic at 2-, 3.9-, 7.5-, and 15.1-year follow-up, respectively. A fifth patient did not progress to collapse or severe osteoarthritis but had residual pain at 2.25-year follow-up. The sixth patient had no symptomatic benefit on enoxaparin but improved on rivaroxaban at 1-year follow-up. Two patients had recurrences of knee pain 1 and 4 years after their initial treatment with enoxaparin. One resolved after a second course of enoxaparin, and the other, with a second recurrence 1 year after the second course, resolved after a third course. Pretreatment, all 6 patients required canes, crutches, or wheelchairs, but after enoxaparin, no patient required them, and walking was unrestricted. Thrombophilia-hypofibrinolysis contributes to the pathogenesis of knee osteonecrosis. Thrombophilic-hypofibrinolytic patients with stage II knee osteonecrosis treated with enoxaparin have had no collapse or progression to severe osteoarthritis, and most have had resolution of pain and restoration of full function. This represents a major improvement compared with the natural history of untreated spontaneous knee osteonecrosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Medical Treatment of Osteonecrosis of the Knee Associated With Thrombophilia-Hypofibrinolysis

Glueck¹,

Freiberg²,

Wang³

2014

Orthopedics

View full text Add to dashboard Cite

show abstract

“…It was found that low levels of pyridoxal-5-phosphat, the coenzyme form vitamin B 6 < 21, 7 nmol/L gave a twofold higher thrombotic risk [ 35 ]. In addition, Zhou et al [ 36 ] reported that there may be a homocysteine-independent role for B-group vitamins in venous thrombosis development. Our finding supports opinion that it may be possibly a homocysteine-independent relationship between low vitamin B 6 level and venous thrombosis.…”

Section: Discussionmentioning

confidence: 99%

Roles of the Oxidative Stress and ADMA in the Development of Deep Venous Thrombosis

Ekim

Şekeroğlu

Balahoroğlu

et al. 2014

Biochemistry Research International

View full text Add to dashboard Cite

Venous thromboembolism has multifactorial origin and occurs in the context of complex interactions between environmental and genetic predisposing factors. Oxidative stress plays an important role in the physiopathology of venous thrombosis. Current study examined the role of oxidative stress and asymmetric dimethylarginine in the development of DVT with the parameters such as serum malondialdehyde (MDA), glutathione peroxidase (GSH-Px), catalase, ADMA, homocysteine, folic acid, vitamin B6, and vitamin B12 levels. Serum MDA levels were found significantly (P < 0.005) high in patients with DVT compared with control group. Additionally, serum B6 levels were found significantly (P < 0.009) low in patients with DVT compared with healthy volunteers. There were no significant differences between the groups in terms of the other parameters (P > 0.05). This study showed that patients with DVT have increased oxidative stress compared with the healthy volunteers whereas there was no significant difference between the groups in terms of serum ADMA levels. Thus serum ADMA levels seemed to be not related with development of DVT.

show abstract

“… 5 Hyperhomocysteinemia due to reduced B-group vitamins (folic acid, vitamin B12, and vitamin B6) levels is thought to be a part of the pathophysiologic link between B-group vitamins and venous thrombosis. 6 Besides, Methylenetetrahydrofolate reductase (MTHFR) gene mutations were supposed to increase the risk of DVT. Increased hyperhomocysteinemia (sometimes be related with MTHFR mutations) seems to be responsible for increased risk of thrombosis.…”

Section: Introductionmentioning

confidence: 99%

Study on relationships among deep vein thrombosis, homocysteine & related B group vitamins

Ekim¹,

Ekim²,

Yılmaz³

et al. 2015

Pak J Med Sci

View full text Add to dashboard Cite

Objectives:Hyperhomocysteinemia has been considered as a potential risk factor for deep venous thrombosis (DVT) but it is still controversy. We aimed to evaluate the prevalence of hyperhomocysteinemia in patients with DVT. Our second objective was to document the prevalence of folate, Vitamin B6, and Vitamin B12 level in this patient population.Methods:Sixty patients with DVT aged from 23 to 84 years, were assessed regarding demographic characteristics, serum levels of homocysteine, folate, vitamin B12, and vitamin B6. The diagnosis of DVT was based upon Wells scoring system and serum D-dimer level and confirmed by deep venous Doppler ultrasonography of the lower limbs.Results:Mean serum homocysteine levels were found significantly higher in patients over the age of 40 years (10.81±4.26 µmol/L vs 9.13±3.23 µmol/L). Of all the patients, 9 patients had homocysteine level above the 15µmol/L, 26 had folic acid level below 3 ng/ml, one had vitamin B12 level below 150 pmol/L, and two had vitamin B6 level below 30 nmol/L. In the hyperhomocysteinemic group, five patients had low folic acid level, one had low vitamin B12 level, and two had low vitamin B6 level.Conclusions:Hyperhomocysteinemia, in women older than 40 years, may be a risk factor for DVT. Folic acid deficiency may also influence serum homocysteine concentrations. Folate therapy may be offered to the patients with DVT. However further studies are required to clarify the underlying molecular mechanisms.

show abstract

Association between B-group vitamins and venous thrombosis: systematic review and meta-analysis of epidemiological studies

Cited by 15 publications

References 33 publications

Medical Treatment of Osteonecrosis of the Knee Associated With Thrombophilia-Hypofibrinolysis

Medical Treatment of Osteonecrosis of the Knee Associated With Thrombophilia-Hypofibrinolysis

Roles of the Oxidative Stress and ADMA in the Development of Deep Venous Thrombosis

Study on relationships among deep vein thrombosis, homocysteine & related B group vitamins

Contact Info

Product

Resources

About